Semaglutide
Approved medicineGet notified when the evidence changes.
The FDA has approved a version of this as a medicine, so it has been through large studies in people.
Compiled and reviewed by the PeptideSearch Editorial Team · Status checked 2026-07-01
Also called Ozempic / Wegovy / Rybelsus / NN9535
A long-acting copy of a gut hormone. Approved for type 2 diabetes and for weight loss, backed by large studies in people.
The basics
- What is it?
- A medicine that copies a gut hormone your body makes after eating, which lowers appetite and blood sugar.
- What do we know?
- A lot. Large studies in tens of thousands of people show clear weight loss and better blood sugar. It is an approved medicine.
- What do we still not know?
- What happens over decades of use, and how much weight comes back after stopping.
Watch: what the research shows
Semaglutide: What The Research Actually Shows
About 16,000 papers mention semaglutide. We hold 139. Whether it works is settled — what's in your vial isn't.
Official status: Pharmacies may compound it · Checked 2026-07-01
Can a doctor prescribe this?
- Small pharmacy (503A)
- Never put forward to FDA
- Large outsourcing facility (503B)
- Never put forward to FDA
FDA approved as a finished drug, and the active ingredient is legally compoundable under 503A.
Why both lines above can be true: this compound is the active ingredient of a drug the FDA has already approved, and a pharmacy may compound with a bulk substance that is “a component of a drug approved by the Secretary” — a separate route in the law from the list of substances put forward for review. So it never had to be nominated for that list. The wording is in section 503A(b)(1)(A)(i)(II) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 353a). The substance must also be made by an FDA-registered establishment and come with a certificate of analysis for each lot.
503A is a pharmacy making a single prescription for one patient. 503B is a facility making batches. They are governed by separate lists. Where a category is shown, it is a position on the FDA's list of substances that have been put forward and are still being worked through — not the final list, which is set by rulemaking. Category 1 means the FDA does not plan to act against a pharmacy that makes it while the review runs.
Lab suppliers we list: 4
Doses used in research
Taken word for word from the studies and trials listed on this page. This is not a recommendation and not a dose for anyone to take.
This is a sample, not the whole literature.
About 16,000 papers mentioning this compound have been published. We show a selected sample of 163 of them, not the full literature. How we choose them · count checked 2026-08-23
- Study in peopleSemaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study.
Diabetes, obesity & metabolism · 2026
- Study in peopleSemaglutide Injection in Indian Patients With Type 2 Diabetes Mellitus: A Randomised, Phase III, Active-Controlled Study.
Diabetes, obesity & metabolism · 2026
- Study in peopleEarly Adjuvant Treatment with Semaglutide After Sleeve Gastrectomy in Patients with Class II-III Obesity: A Prospective Non-Randomized Controlled Study.
Obesity surgery · 2026
- Study in peopleEfficacy and safety of zalfermin co-administered with semaglutide in participants with fibrosis and cirrhosis due to metabolic dysfunction-associated steatohepatitis: a phase 2, dose-ranging, double-blind, randomised controlled trial.
The lancet. Gastroenterology & hepatology · 2026
- Study in peopleSemaglutide Effects on Insulin Sensitivity and β-Cell Function in Patients With Schizophrenia, Prediabetes, and Obesity Treated With Second-Generation Antipsychotics: Findings From the HISTORI Trial, a 30-Week Randomized, Placebo-Controlled Trial With Semaglutide 1.0 mg Weekly.
Diabetes care · 2026
- Study in peopleBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial.
Nature medicine · 2026
- Study in peopleSemaglutide slows epigenetic aging in a randomized trial of HIV-associated lipohypertrophy.
Nature communications · 2026
- Study in peopleEfficacy and safety of once-weekly cagrilintide-semaglutide (CagriSema) in adults with type 2 diabetes inadequately controlled on diet and exercise (REIMAGINE 1): a randomised, double-blind, placebo-controlled, phase 3a study.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleEffects of semaglutide and empagliflozin on markers of endothelial function in persons with type 2 diabetes: A post hoc analysis of a randomized clinical trial.
Journal of diabetes and its complications · 2026
- Study in peopleOnce-weekly semaglutide versus placebo in patients with alcohol use disorder and comorbid obesity: a randomised, double-blind, placebo-controlled trial.
Lancet (London, England) · 2026
- Study in peopleEffects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026
- Study in peopleEffect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study.
Diabetes care · 2026
- Study in peopleShort- and long-term effects of semaglutide 2.4 mg on energy intake, appetite, and food reward: a 60-week, double-blind randomized controlled trial.
The American journal of clinical nutrition · 2026
- Study in peopleEvaluation of the Safety, Efficacy and Pharmacokinetics of BGM0504 in Chinese Adults With Type 2 Diabetes: A Multicentre, Randomised, Controlled and Double-Blind Phase II Trial.
Diabetes, obesity & metabolism · 2026
- Study in peopleCagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleEffects of a 6-week subcutaneous infusion of native GIP alone or as add-on to semaglutide in people with type 2 diabetes: a single-centre, double-blind, parallel-group, randomised, placebo-controlled trial.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleOnce-Weekly Semaglutide in Adults With Daily Cigarette Use: A Randomized Clinical Trial.
JAMA network open · 2026
- Study in peopleEfficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleSemaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial.
Nature medicine · 2026
- Study in peopleShort-term comparative effects of semaglutide, either alone or in conjunction with canagliflozin, on early diabetic kidney disease.
Pakistan journal of pharmaceutical sciences · 2026
- Study in peopleRepurposing semaglutide as an adjunctive treatment for cocaine use disorder: protocol for a randomised controlled trial.
BMJ open · 2026
- Study in peopleEffects of Semaglutide on Body Composition and GFR: A Prespecified Analysis of the SMART Trial.
Clinical journal of the American Society of Nephrology : CJASN · 2026
- Study in peopleEfficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.
Lancet (London, England) · 2026
- Study in peopleRelationship of early rapid weight loss to efficacy and safety of tirzepatide and semaglutide for obesity: SURMOUNT-5 post hoc analysis.
The American journal of medicine · 2026
- Study in peopleAssessment of the Drug-Drug Interaction Potential of Lotiglipron (PF-07081532) with Midazolam, Omeprazole, Dabigatran, Rosuvastatin, and the Oral Contraceptives Levonorgestrel and Ethinyl Estradiol.
Journal of clinical pharmacology · 2026
- Study in peopleElecoglipron, an oral small molecule GLP-1 receptor agonist in adults with type 2 diabetes (SOLSTICE): a multicentre, phase 2b, randomised, placebo-controlled trial.
Lancet (London, England) · 2026
- Study in peopleImpact of semaglutide withdrawal on cardiometabolic profile and physiology of energy balance: Recovery effects after semaglutide termination - The REST trial study protocol.
PloS one · 2026
- Study in peopleKidney and Survival Benefits of Semaglutide in Diabetes With Chronic Kidney Disease: FLOW Trial Cardiovascular Subgroup Analyses.
Journal of the American College of Cardiology · 2026
- Study in peopleEfficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial.
Diabetologia · 2026
- Study in peopleOral Semaglutide and Heart Failure Outcomes in Persons With Type 2 Diabetes: A Secondary Analysis of the SOUL Randomized Clinical Trial.
JAMA internal medicine · 2026
- Study in peopleSemaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
Diabetes, obesity & metabolism · 2026
- Study in peopleImproved quality of life with semaglutide in schizophrenia: Secondary analyses from a randomized controlled trial.
Schizophrenia research · 2026
- Study in peopleSemaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
Nature medicine · 2026
- Study in peopleEffect of Semaglutide on Insulin Dose Reduction in Adults With Type 1 Diabetes and Obesity Using Automated Insulin Delivery Systems: ADJUST-T1D Post Hoc Analysis.
Diabetes care · 2026
- Study in peopleEfficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial.
Lancet (London, England) · 2026
- Study in peopleSemaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.
JAMA psychiatry · 2026
- Study in peopleRenal or Hepatic Impairment Does Not Affect Pharmacokinetics, Safety, or Tolerability of Subcutaneous Cagrilintide.
Clinical pharmacokinetics · 2026
- Study in peopleEffect of Semaglutide on the Inflammatory Biomarker High-Sensitivity CRP in Patients With Established Cardiovascular Disease and Overweight or Obesity in SELECT: A Prespecified Secondary Analysis.
Circulation · 2026
- Study in peopleWeekly and Biweekly Treatment With Bofanglutide Versus Semaglutide in Chinese Patients With Type 2 Diabetes : A Phase 2b Randomized Clinical Trial.
Annals of internal medicine · 2026
- Study in peopleTirzepatide compared with semaglutide in obesity disease: a subpopulation analysis applying Japan Society for the Study of Obesity criteria in the global SURMOUNT-5 trial.
Current medical research and opinion · 2026
- Study in peopleCagrilintide-semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study.
Lancet (London, England) · 2026
- Study in peopleInsulin, Semaglutide and Dapagliflozin in Adults With Type 1 Diabetes: Design and Methods of Triple Therapy for Type 1 Diabetes (TTT1)-An International Phase 3 Clinical Trial.
Diabetes, obesity & metabolism · 2026
- Study in peopleEfficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE).
Diabetes, obesity & metabolism · 2026
- Study in peopleDual Glucagon and GLP-1 Receptor Agonist Survodutide Improves Biomarkers of Beta-Cell Function and Insulin Sensitivity in People With Type 2 Diabetes or Living With Overweight/Obesity.
Diabetes, obesity & metabolism · 2026
- Study in peopleOrforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial.
Nature medicine · 2026
- Study in peopleEfficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.
Diabetes, obesity & metabolism · 2026
- Study in peopleBispecific GLP-1/GLP-2 agonism in advanced type 2 diabetes: preclinical characterization and a randomized, double-blind, placebo-controlled phase I trial.
Nature communications · 2026
- Study in peopleObesity management for kidney TRANSPLANTation: protocol for the vanguard phase of an innovative randomised controlled trial, embedded in routine care (OK-TRANSPLANT 2).
BMJ open · 2026
- Study in peopleEffect of semaglutide on COVID-19 and other infections: an analysis from the FLOW randomized clinical trial.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2026
- Study in peopleSemaglutide for prevention of type 2 diabetes in women with postpartum prediabetes after gestational diabetes: protocol for a Belgian multicentre double-blind randomised placebo-controlled trial.
BMJ open · 2026
- Study in peopleA Computational Trial of Dermal Mechanotransduction in GLP-1 Receptor Agonist-Associated Premature Facial Ageing.
Aesthetic plastic surgery · 2026
- Study in peopleEfficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleOnce-weekly IcoSema versus once-daily insulin glargine U100 in type 2 diabetes management (COMBINE 4): an open-label, multicentre, treat-to-target, randomised, phase 3b trial.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleEffect of semaglutide on kidney outcomes in the SELECT, FLOW, and SOUL trials: a prespecified pooled analysis.
The lancet. Diabetes & endocrinology · 2026
- Study in peopleOral Semaglutide for Alcohol Use Disorder: A Randomized Clinical Trial.
The American journal of psychiatry · 2026
- Study in peopleSemaglutide as adjunct treatment for obesity in adolescents receiving antipsychotic medication (the GOAL trial): protocol for a single-arm, open-label feasibility study.
BMJ open · 2026
- Study in peopleEffects of <i>Dichrostachys glomerata</i> and <i>Cissus quadrangularis</i> Extracts on GLP-1 Secretion and DPP-4 Activity in Overweight and Obese Individuals: A Randomized Controlled Trial.
Medicina (Kaunas, Lithuania) · 2025
- Study in peopleSemaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial.
JAMA psychiatry · 2025
- Study in peopleEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
The New England journal of medicine · 2024
- Study in peopleSemaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes.
The New England journal of medicine · 2024
- Study in peopleSemaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
Lancet (London, England) · 2024
- Study in peopleOnce-Weekly Semaglutide in Persons with Obesity and Knee Osteoarthritis.
The New England journal of medicine · 2024
- Study in peopleSemaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials.
Lancet (London, England) · 2024
- Study in peopleSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
The New England journal of medicine · 2023
- Study in peopleSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.
The New England journal of medicine · 2023
- Study in peopleSemaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial.
The lancet. Gastroenterology & hepatology · 2023
- Study in peopleOral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2023
- Study in peopleEfficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial.
Lancet (London, England) · 2023
- Study in peopleWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension.
Diabetes, obesity & metabolism · 2022
- Study in peopleEffect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
JAMA · 2022
- Study in peopleTwo-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial.
Nature medicine · 2022
- Study in peopleOnce-Weekly Semaglutide in Adolescents with Obesity.
The New England journal of medicine · 2022
- Study in peopleSemaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
The lancet. Diabetes & endocrinology · 2022
- Study in peopleOnce-Weekly Semaglutide in Adults with Overweight or Obesity.
The New England journal of medicine · 2021
- Study in peopleA Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
The New England journal of medicine · 2021
- Study in peopleTirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
The New England journal of medicine · 2021
- Study in peopleSemaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
Lancet (London, England) · 2021
- Study in peopleEffect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial.
JAMA · 2021
- Study in peopleEffect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial.
JAMA · 2021
- Study in peopleThe effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity.
Diabetes, obesity & metabolism · 2021
- Study in peopleSafety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial.
Lancet (London, England) · 2021
- Study in peopleEfficacy and safety of once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes (SUSTAIN 10).
Diabetes & metabolism · 2020
- Study in peopleOral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine · 2019
- Study in peopleOral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Lancet (London, England) · 2019
- Study in peopleOral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Diabetes care · 2019
- Study in peopleEffect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
JAMA · 2019
- Study in peopleSemaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial.
The lancet. Diabetes & endocrinology · 2019
- Study in peopleEfficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
The lancet. Diabetes & endocrinology · 2019
- Study in peopleEfficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
The lancet. Diabetes & endocrinology · 2019
- Study in peopleEfficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
Lancet (London, England) · 2018
- Study in peopleSemaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
The lancet. Diabetes & endocrinology · 2018
- Study in peopleEfficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Diabetes care · 2018
- Study in peopleSemaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial.
The Journal of clinical endocrinology and metabolism · 2018
- Study in peopleEfficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial.
The lancet. Diabetes & endocrinology · 2017
- Study in peopleEffects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity.
Diabetes, obesity & metabolism · 2017
- Study in peopleEfficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
The lancet. Diabetes & endocrinology · 2017
- Study in peopleEffect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
JAMA · 2017
- Study in peopleEfficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
The lancet. Diabetes & endocrinology · 2017
- Study in peopleSemaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
The New England journal of medicine · 2016
- Data from people, not a trialWeight-loss dynamics with tirzepatide versus semaglutide.
PNAS nexus · 2026
- Data from people, not a trialKetoacidosis Risk in Non-diabetic Patients Using Semaglutide Versus Tirzepatide for Obesity: A Disproportionality Analysis of the FDA Adverse Event Reporting System.
Cureus · 2026
- Data from people, not a trialSemaglutide-induced transient intestinal ischemia: A case report.
International journal of clinical pharmacology and therapeutics · 2026
- Data from people, not a trialOcular complications from glucagon-like peptide-1 receptor agonists: Clinical evidence, potential mechanisms, and clinical recommendations.
Journal of the Chinese Medical Association : JCMA · 2026
- Data from people, not a trialHypoglycaemic coma induced by a falsified semaglutide product: a case report.
European journal of hospital pharmacy : science and practice · 2026
- Data from people, not a trialPrevalence and Factors Associated with GLP-1 Receptor Agonist Use for Weight Management Among Overweight and Obese Adults in the Eastern Province of Saudi Arabia.
Healthcare (Basel, Switzerland) · 2026
- Data from people, not a trialIschemic optic neuropathy with semaglutide: global observational analysis of sex- and formulation-specific risk.
The British journal of ophthalmology · 2026
- Data from people, not a trialSex-specific changes in GLP-1RA trends (2019-2024): Impact of FDA approval of semaglutide (Wegovy) for chronic weight management in the United States.
Diabetes, obesity & metabolism · 2026
- Data from people, not a trialGLP-1 medications: use and interest in a representative survey of Finns.
International journal of obesity (2005) · 2026
- Data from people, not a trialGLP-1RA Dispensing in Youth With Type 2 Diabetes: 2020 to 2023.
Pediatrics · 2026
- Data from people, not a trialRoux-en-Y Gastric Bypass Compared to Glucagon-Like Peptide-1 Receptor Agonists is Associated with Lower Out-of-Pocket Costs in Insured Patients with Type 2 Diabetes and Obesity: A Matched Analysis Over Two Years.
Obesity surgery · 2026
- Data from people, not a trialSemaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection.
Biology methods & protocols · 2026
- Data from people, not a trialNew-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching
2026
- Data from people, not a trialSocial Media Discussions of Anti-Diabetic Drugs and the Popularity of GLP-1 Therapies: Content Analysis.
JMIR diabetes · 2026
- Data from people, not a trialSafety Signals of GLP-1 Receptor Agonists: A Multi-Method Pharmacovigilance Analysis of FAERS (2018-2025) With Sensitivity-Stratified Prioritisation, Notoriety-Bias Assessment, and Cross-Database Validation.
Diabetes, obesity & metabolism · 2026
- Data from people, not a trialGLP-1-based incretin therapy is associated with lower incident Alzheimer's disease and cardiorenal events in adults with documented neuropsychiatric, cognitive, or sensory risk.
Biology methods & protocols · 2026
- Data from people, not a trialClass-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting System
2026
- Data from people, not a trialAcute pancreatitis following semaglutide therapy: a case report.
Annals of medicine and surgery (2012) · 2026
- Data from people, not a trial"Ozempic Face": An Emerging Drug-Related Aesthetic Concern and Its Treatment with Endotissutal Bipolar Radiofrequency (RF)-Our Experience.
Journal of clinical medicine · 2025
- Data from people, not a trialBlinded by the drug? A vigilyze signal linking semaglutide to NAION.
International ophthalmology · 2025
- Data from people, not a trialLongitudinal Analysis of Obesity Drug Use and Public Awareness.
JAMA network open · 2025
- Data from people, not a trialSemaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes.
JAMA ophthalmology · 2025
- Dog studyTranscellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist.
Science translational medicine · 2018
- Animal study, larger animalsDiscovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide.
Journal of medicinal chemistry · 2015
- Chemistry or materials paper, not a health studyElectrospun Nanofiber Oral Thin Film Platform for Sublingual Peptide Delivery: A Promising Alternative to Conventional Semaglutide Formulations.
Diabetes, obesity & metabolism · 2026
- Drug information page, not a studySemaglutide
2006
- No abstract available, not yet classifiedIn brief: Rybelsus R2 rebranded as Ozempic.
The Medical letter on drugs and therapeutics · 2026
- Cost-effectiveness of tirzepatide versus semaglutide for patients with obesity or overweight in the US: evidence from the SURMOUNT-5 head-to-head phase-3 trial.
Journal of medical economics · 2026
- From Prescription to Understanding: Medil AI, a Multilingual Mobile Platform for Medication Information, Pill Reminders, Adherence Support, and Between-Visit Communication
2026
- Semaglutide 25 mg Oral Versus Semaglutide 2.4 mg Injectable: An Indirect Treatment Comparison of Weight Loss Outcomes.
Diabetes, obesity & metabolism · 2026
- Semaglutide promotes bone marrow-derived progenitor cell flux towards an anti-inflammatory and pro-regenerative profile in high-risk patients: the SEMA-VR CardioLink-15 trial.
European heart journal · 2026
- Reestimation of Medicare Spending for Semaglutide After Most Favored Nation and Medicare Drug Price Negotiation Announcements.
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research · 2026
- Exploring Weight Loss Medication Discourse: Mixed Methods Analysis of US-Based Facebook Posts.
JMIR infodemiology · 2026
- The Ethics of Ozempic and Wegovy.
Journal of medical ethics · 2026
- Semaglutide showed limited improvements in patients with Alzheimer's disease: Revisiting the evoke and evoke + clinical trials.
Journal of Alzheimer's disease : JAD · 2026
- Ethical considerations for semaglutide use in children.
Archives of disease in childhood · 2026
- Decoding the hallmarks of GLP-1RA weight-loss super-responders.
Biology methods & protocols · 2026
- Misrepresentation of semaglutide in social media.
Naunyn-Schmiedeberg's archives of pharmacology · 2026
- Use of Glucagon-Like Peptide-1 Receptor Agonists in Danish Adolescents and Young Adults 2018-2025.
Obesity (Silver Spring, Md.) · 2026
- How Low Could Semaglutide Prices Fall? An Analysis of Production Cost and Implications for Global Access.
Obesity (Silver Spring, Md.) · 2026
- Efficacy of CagriSema for Reaching Anthropometric Treatment Targets and Cardiometabolic Outcomes: A Secondary, Post hoc Analysis of REDEFINE 1.
Diabetes, obesity & metabolism · 2026
- Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.
Obesity (Silver Spring, Md.) · 2026
- New Weight Loss Drugs: GLP-1 Agonist Use and Side Effects in the United States.
Rand health quarterly · 2025
- Adjunctive Semaglutide in Patients Undergoing Intragastric Balloon for Weight Loss: 12-Month Prospective Comparative Study.
Obesity surgery · 2025
- The unseen risk of Ozempic: NAION and vision damage.
Annals of medicine and surgery (2012) · 2025
- Online Information About Side Effects and Safety Concerns of Semaglutide: Mixed Methods Study of YouTube Videos.
JMIR infodemiology · 2025
- No abstract available, not yet classifiedThe use of semaglutide medicines and risk of non-arteritic anterior ischemic optic neuropathy (NAION).
Saudi medical journal · 2025
- GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Molecular metabolism · 2021
- The Discovery and Development of Liraglutide and Semaglutide.
Frontiers in endocrinology · 2019
- Review of earlier workSemaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms
2026
- Review of earlier workEfficacy and Safety of Semaglutide for Managing Antipsychotic-associated Weight Gain: A Systematic Review and Meta-analysis.
Indian journal of endocrinology and metabolism · 2026
- Review of earlier workEvaluating the Efficacy, Safety, and Practical Considerations of Semaglutide for Weight Loss in Non-Diabetic Adults: A Narrative Review.
Health science reports · 2026
- Review of earlier workThe ethics of Wegovy: promoting autonomy in pediatric care.
Medicine, health care, and philosophy · 2026
- Review of earlier workA Review of the Oral Semaglutide in Adults with Overweight or Obesity (OASIS) Trials Evaluating Oral Semaglutide (Wegovy) for Chronic Weight Management in Adults With Overweight or Obesity.
Cureus · 2026
- Review of earlier workPharmacogenomics of GLP-1 Receptor Agonists: Precision Medicine in the Age of Ozempic and Mounjaro
2026
- Review of earlier workReply: The ethics of Ozempic and Wegovy.
Journal of medical ethics · 2026
- Review of earlier workThe GLP-1 Nutritional Paradox: A Global Meta-Analysis of Sarcopenic Risks and Micronutrient Gaps in the Post-Obesity Era
2026
- Review of earlier workEffect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.
Journal of cardiovascular development and disease · 2026
- Review of earlier workGLP-1 and GIP class drugs have neuroprotective properties in Alzheimer's and Parkinson's disease.
Frontiers in neuroscience · 2026
- Review of earlier workOral small-molecule GLP-1 receptor agonists: a new Frontier in cardiometabolic medicine.
Frontiers in pharmacology · 2026
- Review of earlier workComparative Efficacy and Safety of Tirzepatide Versus Semaglutide for Obesity: A Systematic Review.
Cureus · 2026
- Review of earlier workSemaglutide in Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.
Cureus · 2025
- Review of earlier workComparative Efficacy of Tirzepatide vs. Semaglutide in Reducing Body Weight in Humans: A Systematic Review and Meta-Analysis of Clinical Trials and Real-World Data.
Journal of clinical medicine research · 2025
- Review of earlier workCardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
The lancet. Diabetes & endocrinology · 2019
Spot an error? corrections@peptidesearch.org